Delek (DK) Stock Declines 6.1% Despite Beating on Q3 Earnings

Published on November 26, 2021

Delek's (DK) total operating expenses in the third quarter rise 36.1% from the prior-year period's figure to $2,910.7 million.

Continue reading on website
Other news

4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio

November 26, 2021
Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.

Ligand's (LGND) Drug-Developing Technologies Holds Potential

November 26, 2021
Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.